For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

Signs and symptoms of low ... (except for switching to non-study tirzepatide or semaglutide). This estimand assumes that participants who had weight loss procedures during the study did not ...

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically ...

A popular weight-loss drug may be changing how doctors treat obesity—but scientists are just starting to uncover exactly how ...

SO-CALLED “miracle” weight-loss jabs are far less effective in the real world than in clinical trials, a major study has revealed. The new findings could have big implications for Brits ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China.

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy ...